Raymond Chen
Pfizer
15 Papers
152 Citations
Raymond Chen is an academic researcher from Pfizer. The author has contributed to research in topics: Chemistry & Size-exclusion chromatography. The author has an hindex of 7, co-authored 15 publications.
Chat about Author
Papers
Automated peak tracking for comprehensive impurity profiling in orthogonal liquid chromatographic separation using mass spectrometric detection.
TL;DR: The development of the fully automated Comprehensive Orthogonal Method Evaluation Technology (COMET) system, which provides automated generic impurities screening for any drug sample and is well suited for efficient drug development and ensuring the quality and safety of drug products.
53
Absolute molecular weight determination of hypromellose acetate succinate by size exclusion chromatography: Use of a multi angle laser light scattering detector and a mixed solvent
TL;DR: This effort to develop a SEC method using a mass sensitive multi angle laser light scattering detector (MALLS) to determine molecular weight distributions of HPMCAS polymers is evaluated and it is demonstrated that the method is accurate and robust.
31
Utilization of ReactIR in Fit for Purpose Process Enablement
TL;DR: In this paper, an efficient four-step synthesis of 1 was described in which utilization of ReactIR was key to efficient processing and reaction monitoring, and key chemical steps included nucleophilic aromatic substitution, iron reduction of aromatic nitro group to aniline, decarboxylation, and ester formation.
21
Multikilogram Synthesis of a Hepatoselective Glucokinase Activator
Joshua R. Dunetz,Martin A. Berliner,Yanqiao Xiang,Timothy L. Houck,Salingue Fabrice Henri,Wang Chao,Chen Yuandong,Wang Shenghua,Yun Huang,Douglas Farrand,Steven J. Boucher,David B. Damon,Teresa W. Makowski,Mark T. Barrila,Raymond Chen,Isamir Martínez +15 more
TL;DR: This work describes the process development and manufacture of early-stage clinical supplies of a hepatoselective glucokinase activator, a potential therapy for type 2 diabetes mellitus, with critical issues centered on challenges associated with the synthesis of intermediates and API bearing a particularly racemization-prone α-aryl carboxylate functionality.
18
Development and validation of a Level A in-vitro in-vivo correlation for tofacitinib modified-release tablets using extrudable core system osmotic delivery technology
Joseph Kushner,Manisha Lamba,Thomas C. Stock,Ronnie Wang,Mary Anne Nemeth,Christine Alvey,Raymond Chen,Vincent DeMatteo,Andrew Blanchard +8 more
TL;DR: This study demonstrates that the tofacitinib ECS Osmotic tablet platform can achieve a Level A IVIVC, similar to other osmotic delivery systems.
18